Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rutin + Tislelizumab + GC in Platinum-refractory MIBC
NCT06916494Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rutin in muscle-invasive bladder cancer (MIBC), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Tumor microenvironment at 6 weeks. Started May 2025; status: recruiting.
02
Drugs
rutin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06916494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916494.